SHL Share Price Performance
AU$0
-27.55 (-100.00%)
Price AU$0
Fair ValueAU$24.41
Share Pricen/a
Narrative Update • Jul 16
Sonic Healthcare Limited Stock Price
- 5 Narratives written by author
- 4 Comments on narratives written by author
- 138 Fair Values set on narratives written by author
SHL Community Narratives
AN
Fair Value
·Fair Value AU$24.41 14.8% undervalued intrinsic discount
Digital Pathology And Global Expansion Will Define Healthcare
1users have liked this narrative
4users have commented on this narrative
67users have followed this narrative
AN
Fair Value
·Fair Value AU$18 15.6% overvalued intrinsic discount
Genetics And Radiology Services Will Support Steady Margins And Fairly Priced Prospects
0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
CH
Fair Value
·Fair Value AU$30 30.7% undervalued intrinsic discount
Sonic Healthcare Is Priced for Yesterday. Its AI Is Built for Tomorrow.
1users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
Sonic Healthcare is poised for large upside as margins recover
Sonic Healthcare (ASX: SHL) is a stock the market currently seems to be pricing for permanent disappointment rather than temporary difficulty. Shares have fallen 23.3% over the past year to A$21.12, sitting below even the lowest analyst target of A$18.Read more
Sonic Healthcare Is Priced for Yesterday. Its AI Is Built for Tomorrow.
Sonic Healthcare stands as the world’s third-largest medical diagnostics company, operating an extensive network of pathology labs, radiology centers, and primary care medical practices across Australia, the US, Germany, Switzerland, and the UK. Founded in 1987, the company has spent over three decades executing a disciplined acquisition strategy to become a cornerstone of global healthcare infrastructure.Read more
Radiology And Genetics Demand Will Transform This Diagnostics Consolidator Over The Next Decade
Sonic Healthcare looks set to benefit as more hospitals and health systems send out testing work and as demand grows for advanced scans and genetic tests. The big question is whether it can pull off its lab mergers and acquisitions fast enough while rules, contracts, and financing costs stay friendly.Read more
AN
AU$32
35.0% undervalued intrinsic discount
Fair Value
Revenue
5.79% p.a.
Profit Margin
7.51%
Future PE
22.94x
Price in 2029
AU$39.5
Genetics And Radiology Services Will Support Steady Margins And Fairly Priced Prospects
Sonic Healthcare is leaning on genetics testing and higher-end imaging to lift results, but the payoff may take longer than investors expect because new labs, tech rollouts, and big contract ramp-ups are hard to execute smoothly. The bigger question is whether pricing pressure and integration work keep profits stuck even as test volumes and new services grow.Read more
AN
AU$18
15.6% overvalued intrinsic discount
Fair Value
Revenue
5.32% p.a.
Profit Margin
6.4%
Future PE
15.39x
Price in 2029
AU$22.28
Digital Pathology And Global Expansion Will Define Healthcare
Sonic Healthcare is leaning into genetic testing, digital pathology, and bigger international deals to sell more complex tests and run labs more efficiently. But the same plan brings big execution risks, from integrating new businesses to shifting health rules and fierce price competition.Read more
AN
AU$24.41
14.8% undervalued intrinsic discount
Fair Value
Revenue
4.81% p.a.
Profit Margin
6.88%
Future PE
19.66x
Price in 2029
AU$30.18
Trending Discussion
No trending discussion available.
Recently Updated Narratives
DA
Sonic Healthcare is poised for large upside as margins recover
Fair Value: AU$27 23.0% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
CH
Sonic Healthcare Is Priced for Yesterday. Its AI Is Built for Tomorrow.
Fair Value: AU$30 30.7% undervalued intrinsic discount
7 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
SHL: Margin Recovery And Cost Efficiencies Will Support A Re-Rating
Fair Value: AU$32 35.0% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Sonic Healthcare Limited Key Details
About SHL
- Founded
- 1934
- Employees
- 45000
- CEO
- WebsiteView website
Sonic Healthcare Limited offers medical diagnostic services, and administrative services and facilities to medical practitioners in Australia, the United States, Germany, and internationally. The company provides laboratory medicine/pathology testing services, such as biochemistry, cytopathology, genetics, haematology, histopathology, immunoserology, microbiology, molecular pathology, prenatal testing, toxicology, and ancillary functions; and radiology services, including magnetic resonance imaging, computed tomography (CT), ultrasound, X-ray, mammography, nuclear medicine, PET CT, interventional procedures, and bone mineral densitometry. It also offers primary care medical services comprising general practice clinics, occupational health services, skin cancer clinics, general practice IT solutions, and community-based healthcare services, as well as clinical trials services. Sonic Healthcare Limited was incorporated in 1934 and is headquartered in Sydney, Australia.
Recent SHL News & Updates
Narrative Update • Jul 02
SHL: Higher Discount Rate Will Pressure Future Earnings Multiple
Analysts have reduced their price target on Sonic Healthcare from A$23.00 to A$18.00, citing updated assumptions that include a higher discount rate, more moderate revenue growth expectations, a slightly stronger profit margin profile, and a lower future P/E multiple. What’s in the News for Sonic Healthcare No major recent news items for Sonic Healthcare have been identified from the provided primary sources.
Narrative Update • Jun 18
